Cargando…

Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review

Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LE...

Descripción completa

Detalles Bibliográficos
Autores principales: Sam Saji, Alen, Yang, Biao, Hou, Wan Ting, Liu, Xia, Ren, Qiu Ping, Wei, Yuan Feng, Zhang, Yu Zu, Yang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971717/
https://www.ncbi.nlm.nih.gov/pubmed/36865802
http://dx.doi.org/10.3389/fonc.2023.1090580
_version_ 1784898157742653440
author Sam Saji, Alen
Yang, Biao
Hou, Wan Ting
Liu, Xia
Ren, Qiu Ping
Wei, Yuan Feng
Zhang, Yu Zu
Yang, Xi
author_facet Sam Saji, Alen
Yang, Biao
Hou, Wan Ting
Liu, Xia
Ren, Qiu Ping
Wei, Yuan Feng
Zhang, Yu Zu
Yang, Xi
author_sort Sam Saji, Alen
collection PubMed
description Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LELCC without Epstein–Barr virus (EBV) infection having been reported worldwide. The treatment of LELCC remains unexplored. Here, we present two cases of patients with LELCC without EBV infection who were treated by liver resection, chemotherapy, and immunotherapy and who achieved long survival time. The patients received surgery to remove the tumors and then adjuvant chemotherapy using the GS regimen and combined immunotherapy involving natural killer–cytokine-induced killer (NK-CIK) and nivolumab were performed. Both patients had a good prognosis with a survival time of more than 100 months and 85 months.
format Online
Article
Text
id pubmed-9971717
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99717172023-03-01 Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review Sam Saji, Alen Yang, Biao Hou, Wan Ting Liu, Xia Ren, Qiu Ping Wei, Yuan Feng Zhang, Yu Zu Yang, Xi Front Oncol Oncology Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LELCC without Epstein–Barr virus (EBV) infection having been reported worldwide. The treatment of LELCC remains unexplored. Here, we present two cases of patients with LELCC without EBV infection who were treated by liver resection, chemotherapy, and immunotherapy and who achieved long survival time. The patients received surgery to remove the tumors and then adjuvant chemotherapy using the GS regimen and combined immunotherapy involving natural killer–cytokine-induced killer (NK-CIK) and nivolumab were performed. Both patients had a good prognosis with a survival time of more than 100 months and 85 months. Frontiers Media S.A. 2023-01-30 /pmc/articles/PMC9971717/ /pubmed/36865802 http://dx.doi.org/10.3389/fonc.2023.1090580 Text en Copyright © 2023 Sam Saji, Yang, Hou, Liu, Ren, Wei, Zhang and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Sam Saji, Alen
Yang, Biao
Hou, Wan Ting
Liu, Xia
Ren, Qiu Ping
Wei, Yuan Feng
Zhang, Yu Zu
Yang, Xi
Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
title Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
title_full Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
title_fullStr Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
title_full_unstemmed Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
title_short Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
title_sort combined nk-cik and pd-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with ebv infection: two case reports and a literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971717/
https://www.ncbi.nlm.nih.gov/pubmed/36865802
http://dx.doi.org/10.3389/fonc.2023.1090580
work_keys_str_mv AT samsajialen combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview
AT yangbiao combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview
AT houwanting combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview
AT liuxia combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview
AT renqiuping combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview
AT weiyuanfeng combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview
AT zhangyuzu combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview
AT yangxi combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview